Replies to post #189976 on Biotech Values

[biocqr]

Thank you! It appears that AAVL is exploring two paths for AVA-101 approval... as a direct competitor to Lucentis/Avastin/Eylea and as rescue therapy for anti-VEGF refractory patients. Given the decline in efficacy over time with anti-VEGF injections, the refractory population could be substantial. Do you believe AVA-101 might have a better chance as rescue therapy?

[lgonber]

AAVL: Reading your comments on AAVL and AMD, but the company prior focus and first product is subretinal. any opinion on success on this?